Professor Nir Peled, MD, PhD, FCCP

Professor Nir Peled, MD, PhD, FCCP

Pulmonologist and Medical Oncologist
Thoracic Cancer Unit
Davidoff Cancer Center
Tiqwa, Israel 

Related Videos

What is the role of liquid biopsies and hybrid capture NGS in the face of our understanding that there is sub-clonal evolution in many solid tumors? Video

What is the role of liquid biopsies and hybrid capture NGS in the face of our understanding that there is sub-clonal evolution in many solid tumors?

What is the role of liquid biopsies and hybrid capture NGS in the face of our understanding that there is sub-clonal evolution in many solid tumors?

What other gene rearrangements (ie, gene fusions) have recently been identified (such as ROS1, BRAF, RET) that are susceptible to targeted therapies? What are the current clinical implications for testing? Video

What other gene rearrangements (ie, gene fusions) have recently been identified (such as ROS1, BRAF, RET) that are susceptible to targeted therapies? What are the current clinical implications for testing?

What other gene rearrangements (ie, gene fusions) have recently been identified (such as ROS1, BRAF, RET) that are susceptible to targeted therapies? What are the current clinical implications for testing?

What is the importance of finding EGFR-sensitizing mutations such as exon 19 or exon 21 in NSCLC? What is their relationship to sensitivity to TKIs, such as erlotinib, gefitinib, and afatinib? Video

What is the importance of finding EGFR-sensitizing mutations such as exon 19 or exon 21 in NSCLC? What is their relationship to sensitivity to TKIs, such as erlotinib, gefitinib, and afatinib?

What is the importance of finding EGFR-sensitizing mutations such as exon 19 or exon 21 in NSCLC? What is their relationship to sensitivity to TKIs, such as erlotinib, gefitinib, and afatinib?

What is the additional clinical value of using a hybrid capture-based NGS platform? Can you discuss in terms of false-negativity and sensitivity analyses? Video

What is the additional clinical value of using a hybrid capture-based NGS platform? Can you discuss in terms of false-negativity and sensitivity analyses?

What is the additional clinical value of using a hybrid capture-based NGS platform? Can you discuss in terms of false-negativity and sensitivity analyses?

What is the rationale for using a validated genomic profiling platform that uses high sensitivity, hybrid capture-based NGS methodology to assess molecular drivers in solid tumors? Video

What is the rationale for using a validated genomic profiling platform that uses high sensitivity, hybrid capture-based NGS methodology to assess molecular drivers in solid tumors?

What is the rationale for using a validated genomic profiling platform that uses high sensitivity, hybrid capture-based NGS methodology to assess molecular drivers in solid tumors?

Can you bring genomic profiling down to the oncologist-patient level and explain what a FoundationOne Report is, how long it takes to generate, and what the translational value is? Video

Can you bring genomic profiling down to the oncologist-patient level and explain what a FoundationOne Report is, how long it takes to generate, and what the translational value is?

Can you bring comprehensive genomic profiling down to the oncologist-cancer patient level and explain what a FoundationOne Report looks like, what information it contains, how long it takes to generate a report and what the translational ...

What advances in therapeutic targeting with NGS comprehensive genomic profiling and multiplex testing have we witnessed in patients with NSCLC? Video

What advances in therapeutic targeting with NGS comprehensive genomic profiling and multiplex testing have we witnessed in patients with NSCLC?

What advances in therapeutic targeting with NGS comprehensive genomic profiling and multiplex testing have we witnessed in patients with NSCLC?

What is the unique status of hybrid capture NGS within the context of molecular target-driven therapy for solid tumors? Video

What is the unique status of hybrid capture NGS within the context of molecular target-driven therapy for solid tumors?

What is the unique status of hybrid capture NGS within the context of molecular target-driven therapy for solid tumors?